SI2095822T1 - Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide - Google Patents

Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide

Info

Publication number
SI2095822T1
SI2095822T1 SI200631689T SI200631689T SI2095822T1 SI 2095822 T1 SI2095822 T1 SI 2095822T1 SI 200631689 T SI200631689 T SI 200631689T SI 200631689 T SI200631689 T SI 200631689T SI 2095822 T1 SI2095822 T1 SI 2095822T1
Authority
SI
Slovenia
Prior art keywords
peptides
growth factor
vascular endothelial
factor receptor
endothelial growth
Prior art date
Application number
SI200631689T
Other languages
English (en)
Slovenian (sl)
Inventor
Hideaki Tahara
Takuya Tsunoda
Masabumi Shibuya
Shuichi Nakatsuru
Original Assignee
Oncotherapy Science, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science, Inc. filed Critical Oncotherapy Science, Inc.
Publication of SI2095822T1 publication Critical patent/SI2095822T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
SI200631689T 2005-02-28 2006-02-17 Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide SI2095822T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65752705P 2005-02-28 2005-02-28
EP09007549.0A EP2095822B1 (en) 2005-02-28 2006-02-17 Epitope peptides derived from vascular endothelial growth factor receptor 1 and vaccines containing these peptides

Publications (1)

Publication Number Publication Date
SI2095822T1 true SI2095822T1 (sl) 2013-12-31

Family

ID=36581423

Family Applications (3)

Application Number Title Priority Date Filing Date
SI200631689T SI2095822T1 (sl) 2005-02-28 2006-02-17 Peptidi epitopov, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja, in cepiva, ki vsebujejo te peptide
SI200631668T SI2289533T1 (sl) 2005-02-28 2006-02-17 Epitopni peptidi, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja in cepiva, ki vsebujejo te peptide
SI200631350T SI1855707T1 (sl) 2005-02-28 2006-02-17 Peptidi epitopov izpeljani iz receptorja vaskularnega endotelijskega rastnega faktorja in cepiva ki vsebujejo te peptide

Family Applications After (2)

Application Number Title Priority Date Filing Date
SI200631668T SI2289533T1 (sl) 2005-02-28 2006-02-17 Epitopni peptidi, izpeljani iz receptorja 1 vaskularnega endotelijskega rastnega faktorja in cepiva, ki vsebujejo te peptide
SI200631350T SI1855707T1 (sl) 2005-02-28 2006-02-17 Peptidi epitopov izpeljani iz receptorja vaskularnega endotelijskega rastnega faktorja in cepiva ki vsebujejo te peptide

Country Status (10)

Country Link
US (4) US7919099B2 (enExample)
EP (4) EP1855707B1 (enExample)
JP (3) JP4931154B2 (enExample)
CY (1) CY1112867T1 (enExample)
DK (3) DK2289533T3 (enExample)
ES (3) ES2435650T3 (enExample)
PL (3) PL2095822T3 (enExample)
PT (3) PT2289533E (enExample)
SI (3) SI2095822T1 (enExample)
WO (1) WO2006093030A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
CN101678065A (zh) * 2007-02-16 2010-03-24 肿瘤疗法科学股份有限公司 脉络膜血管新生的疫苗疗法
TW201109029A (en) * 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization
US20150359864A1 (en) * 2012-03-09 2015-12-17 Oncotherapy Science, Inc. Pharmaceutical composition containing peptides
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20250057128A (ko) 2015-12-30 2025-04-28 코디악 사이언시스 인코포레이티드 항체 및 이의 접합체
US20200147194A1 (en) * 2017-05-19 2020-05-14 Keio University Peptide vaccine and peptide vaccine composition for cranial nerve disease
JP2021514656A (ja) 2018-03-02 2021-06-17 コディアック サイエンシーズ インコーポレイテッドＫｏｄｉａｋ Ｓｃｉｅｎｃｅｓ Ｉｎｃ． Ｉｌ−６抗体ならびにその融合構築物およびコンジュゲート
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
JPH0418667A (ja) * 1989-07-05 1992-01-22 Tohoku Nippon Denki Software Kk 自動配送システム
JPH0350140A (ja) * 1989-07-18 1991-03-04 Seiko Epson Corp 分布屈折率レンズの製造方法
ES2230542T3 (es) 1993-03-25 2005-05-01 MERCK & CO., INC. Inhibidor del factor de crecimiento celular endotelial vascular.
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
AU6632496A (en) 1995-08-03 1997-03-05 Rijksuniversiteit Te Leiden Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6100071A (en) * 1996-05-07 2000-08-08 Genentech, Inc. Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production
WO1998004720A1 (en) 1996-07-26 1998-02-05 Sloan-Kettering Institute For Cancer Research Method and reagents for genetic immunization
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US6200954B1 (en) * 1998-09-04 2001-03-13 National University Of Singapore Small peptides having potent anti-angiogenic activity
WO2002072627A2 (en) * 2001-03-09 2002-09-19 Callistogen Ag Induction of anti-tumor cytotoxic t-lymphocytes in humans using peptide epitopes found by computer based algorithms for vaccination
FI110549B (fi) 2001-06-29 2003-02-14 Nokia Corp Menetelmä ja järjestely liikkeen määrittämiseksi
US20030157101A1 (en) 2001-11-15 2003-08-21 Carlo Gambacorti-Passerini Immunogenic ALK peptides
JP4035845B2 (ja) 2001-12-10 2008-01-23 株式会社グリーンペプタイド 腫瘍抗原
CU23178A1 (es) * 2002-04-15 2006-09-22 Ct Ingenieria Genetica Biotech INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA
JP2004018667A (ja) 2002-06-17 2004-01-22 National Institute Of Advanced Industrial & Technology 高分子化合物膜の表面における炭酸カルシウム被膜の製造方法
JP4406607B2 (ja) 2002-08-26 2010-02-03 オンコセラピー・サイエンス株式会社 ペプチド及びこれを含む医薬
ES2375299T3 (es) * 2002-09-12 2012-02-28 Oncotherapy Science, Inc. Péptidos kdr y vacunas que los contienen.
TW201109029A (en) 2009-06-11 2011-03-16 Oncotherapy Science Inc Vaccine therapy for choroidal neovascularization

Also Published As

Publication number Publication date
PL1855707T3 (pl) 2012-08-31
ES2435650T3 (es) 2013-12-20
JP2008531463A (ja) 2008-08-14
WO2006093030A1 (en) 2006-09-08
US7919099B2 (en) 2011-04-05
DK2289533T3 (da) 2013-12-02
PT2289533E (pt) 2013-12-10
JP4931154B2 (ja) 2012-05-16
CY1112867T1 (el) 2016-04-13
PT1855707E (pt) 2012-05-25
ES2385396T3 (es) 2012-07-24
SI1855707T1 (sl) 2012-07-31
JP2012102105A (ja) 2012-05-31
US20140186381A1 (en) 2014-07-03
PT2095822E (pt) 2013-12-09
JP2010265269A (ja) 2010-11-25
DK1855707T3 (da) 2012-07-16
DK2095822T3 (da) 2014-01-13
EP2289533B1 (en) 2013-09-18
US20110250219A1 (en) 2011-10-13
EP2095822A1 (en) 2009-09-02
US8257711B2 (en) 2012-09-04
ES2442294T3 (es) 2014-02-11
EP1855707A1 (en) 2007-11-21
PL2095822T3 (pl) 2014-03-31
HK1152873A1 (en) 2012-03-16
JP5789820B2 (ja) 2015-10-07
EP2289533A1 (en) 2011-03-02
SI2289533T1 (sl) 2013-11-29
EP2095822B1 (en) 2013-10-16
US20120294877A1 (en) 2012-11-22
US20090214581A1 (en) 2009-08-27
HK1133601A1 (en) 2010-04-01
JP4843095B2 (ja) 2011-12-21
PL2289533T3 (pl) 2014-02-28
EP1855707B1 (en) 2012-04-04
US8663647B2 (en) 2014-03-04
EP2289532A1 (en) 2011-03-02
HK1110529A1 (en) 2008-07-18

Similar Documents

Publication Publication Date Title
IL178070A (en) Antibiotic p-selectin antibodies and pharmaceuticals that include them
SI1819358T1 (sl) Protitelesa proti receptorju 1 za vaskularni endotelijski rastni dejavnik (vegfr-1)
IL230645A (en) Antibodies against activin a or b and their use to promote bone growth
GB2463586B (en) li-key/antigenic epitope hybrid peptide vaccines
PL2272873T3 (pl) Przeciwciała przeciw receptorowi insulinopodobnego czynnika wzrostu I i ich zastosowania
GB2420499B (en) Spinal prostheses
IL182267A0 (en) Novel anthranilamide pyridinureas as vascular endothelial growth factor
IL163699A0 (en) Endothelial cells derived from human embryonic stem cells
GB0522434D0 (en) Merchandisers having anti-fog coatings and methods for making the same
EP1879516A4 (en) IMPLANT OF STABILIZATION OF VERTEBRATES
SI1855707T1 (sl) Peptidi epitopov izpeljani iz receptorja vaskularnega endotelijskega rastnega faktorja in cepiva ki vsebujejo te peptide
AU304285S (en) Cosmetic container
EP1948676A4 (en) CONJUGATE BASED ON BLOOD PROTEIN AND BIOACTIVE SUBSTANCE
IL210861A (en) Milk epitope peptides and vaccines containing them
IL212046A0 (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same
ZA200801874B (en) Antigenic peptides and their use
ZA200701496B (en) Post-foaming dental mousse and methods utilizing the same
GB0427301D0 (en) Bone support
ZA201104890B (en) Wdrpuh epitope peptides and vaccines containing the same
GB2417482B (en) Box or container support
EP1881843A4 (en) KINASEPEPTIDES AND ANTIBODIES
PL1874712T3 (pl) Wytwarzanie jodku metylu znakowanego <sup>11</sup>C oraz radioligandu 11C GB67
GB0418390D0 (en) Pot handler & cane support
AU2003214396A1 (en) The use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
GB0508752D0 (en) Plant and container support